Skip to main content
. 2022 Sep 4;20:391. doi: 10.1186/s12967-022-03592-4

Fig. 3.

Fig. 3

Confirmed tumor response on whole body 18F-FDG PET/CT MIP images obtained in a66 year old male stage IV-M1c melanoma patient with a BRAF N486_P590del (in-frame deletion, class II BRAF mutation) treated with trametinib 2 mg QD plus dabrafenib 50 mg BID